Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Total Current Liabilities (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Total Current Liabilities for 6 consecutive years, with $77.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities rose 14.99% year-over-year to $77.8 million, compared with a TTM value of $77.8 million through Dec 2025, up 14.99%, and an annual FY2025 reading of $77.8 million, up 14.99% over the prior year.
  • Total Current Liabilities was $77.8 million for Q4 2025 at Cytek Biosciences, up from $67.7 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $77.8 million in Q4 2025 and bottomed at $28.2 million in Q2 2021.
  • Average Total Current Liabilities over 5 years is $50.7 million, with a median of $51.3 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities skyrocketed 50.36% in 2022, then grew 14.65% in 2023.
  • Year by year, Total Current Liabilities stood at $33.2 million in 2021, then surged by 47.8% to $49.0 million in 2022, then increased by 14.65% to $56.2 million in 2023, then increased by 20.34% to $67.7 million in 2024, then increased by 14.99% to $77.8 million in 2025.
  • Business Quant data shows Total Current Liabilities for CTKB at $77.8 million in Q4 2025, $67.7 million in Q1 2025, and $67.7 million in Q4 2024.